NASDAQ: GRAL - GRAIL, LLC

Yield per half year: +95.71%
Dividend yield: 0.00%
Sector: Healthcare

Share chart GRAIL, LLC

Extended chart Simple chart
Financial Markets by TradingView

About GRAIL, LLC

GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.

Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2024-06-25
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://grail.com
Цена ао 28.39
Change price per day: -5.77% (28.58)
Change price per week: -11.09% (30.29)
Change price per month: -38.61% (43.87)
Change price per 3 month: +37.4% (19.6)
Change price per half year: +95.71% (13.76)
Change price per year to date: +37.4% (19.6)
All parameters

Underestimation

Title Value Grade
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0.0202 10
Total: 3.75

Efficiency

Title Value Grade
ROA, % -32.16 0
ROE, % -40.2 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.1323 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 537.18 10
Yield Ebitda, % 155.37 10
Yield EPS, % 499.75 10
Total: 10
More

ETFShare, %Profitability for 1 year, %Dividends, %
Principal Healthcare Innovators ETF 0.04203 618.5 0.8416
Future Tech ETF 0.04203 426.34 0.8416
iShares Russell Mid-Cap Value ETF 0.00401 18.01 2.03934
iShares Russell Midcap ETF 0.00308 20.77 1.71565
iShares Russell 1000 Value ETF 0.00147 17.45 2.15361
iShares U.S. Tech Independence Focused ETF 0.00083 34.94 0.84412
iShares Russell 3000 ETF 0.00067 24.83 1.43482
0.01165.831.41



Head Job title Payment Year of birth
Mr. Robert P. Ragusa CEO & Director 1960 (65 years)
Dr. Joshua J. Ofman M.D., M.S.H.S President 1965 (60 years)
Mr. Aaron Freidin Chief Financial Officer
Mr. Paul Ciccolella Senior VP of Global Development & Operations
Ms. Amoolya Singh Ph.D. Senior VP of Research & Chief Scientific Officer
Mr. Abram Barth J.D., M.P.H. General Counsel
Ms. Julie Currie Chief People Officer
Mr. Rodger Currie VP and Head of Government Affairs & Alliance Development
Sir Harpal S. Kumar M.A., M.B.A., MA, MBA, MEng President Biopharma Business & Europe
Dr. Satnam Alag Ph.D. Senior VP of Software Engineering & Chief Security Officer

Address: United States, Menlo Park, 1525 O’Brien Drive - open in Google maps, open in Yandex maps
Website: https://grail.com